REFERENCE DESK / COMMON QUESTIONS
Questions, answered to the evidence
Direct answers on identity, mechanisms, claims, approvals, and the limits of current peptide research.
What does a GHK-Cu peptide do?
GHK-Cu binds copper and participates in signaling associated with extracellular-matrix production, tissue remodeling, antioxidant activity, and repair. Human evidence is concentrated in topical skin and hair-adjacent work, while many broader claims come from cells, animals, or reviews [1][3][6]. It is more accurate to describe what each model found than to assign the peptide one universal effect.
What is GHK-Cu and how does it work?
GHK is a three-amino-acid sequence; GHK-Cu is its copper complex. The copper-bound form can present copper to biological systems and influence fibroblast activity, matrix turnover, and several repair-related signaling programs. Cultured human fibroblasts increased collagen synthesis without a change in cell number [7]. Delivery through intact skin remains a formulation challenge [1].
Is GHK-Cu peptide really anti-aging?
“Anti-aging” is too broad for the evidence. Reviews and small topical studies report changes in procollagen, collagen production, and some skin measures [1][4]. Those findings support continued skin research. They do not prove whole-body age reversal, and broad gene-expression results should not be read as clinical rejuvenation [2].
What is the difference between GHK and GHK-Cu?
GHK is the free tripeptide glycyl-histidyl-lysine. GHK-Cu is that peptide coordinated to a copper ion. Copper binding is part of the proposed biological activity, so studies of free GHK and the intact complex are not automatically interchangeable.
What is semaglutide used for?
Semaglutide is an approved prescription GLP-1 receptor agonist with specific formulations and indications. Large trials have studied weight management, cardiovascular outcomes, and kidney outcomes in defined populations [9][10][11]. The approved label for a given product sets its use; a literature summary does not provide individual treatment guidance.
How does semaglutide work for weight loss?
Semaglutide activates GLP-1 receptors in metabolic and appetite pathways. It increases satiety, reduces food intake, slows gastric emptying, and supports glucose-dependent insulin signaling. A randomized trial found a greater mean body-weight reduction than placebo in adults with overweight or obesity without diabetes [11].
What is tesamorelin?
Tesamorelin is a synthetic GHRH analogue. It prompts the pituitary to release endogenous growth hormone, which raises IGF-1 and influences fat metabolism. Its US approval is limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy [14].
Will tesamorelin help with ordinary belly fat?
The strongest trials concern visceral fat in adults with HIV-associated lipodystrophy [13][15][17]. Those findings cannot be assumed to apply to general abdominal weight loss, healthy aging, or physique goals. This site does not turn a population-specific result into a personal recommendation.
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic fifteen-amino-acid peptide, not growth hormone. Some laboratory work discusses growth-related or repair signaling, but its clearest mechanistic literature centers on pathways such as VEGFR2-linked angiogenesis [21].
What does BPC-157 do in the body?
That question is not settled in humans. In animal and cell models, BPC-157 has been linked to angiogenesis, gastric protection, and repair pathways [21][22]. A recent review found human evidence extremely limited and large rigorous trials absent [19]. Model findings should not be restated as proven human effects.
Does BPC-157 work immediately?
Published evidence does not establish a reliable human onset of benefit. Online timing claims are anecdotal, not clinical evidence. The available human pilot literature is too small to define effectiveness, onset, or a dependable safety profile [18][19].
Does BPC-157 damage the liver?
The available human evidence is far too thin to answer that question confidently. A tiny pilot observed no measured hepatic biomarker change in two healthy adults [18], but that cannot rule out uncommon, delayed, or context-specific injury. Reviews continue to classify the compound as investigational [19].